Navigation Links
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
Date:11/9/2008

ed, AstraZeneca (NYSE: AZN) expects to file a regulatory submission including the JUPITER data in the first half of 2009 and if approved, will begin promotional activities within the approved labeling.

Rosuvastatin is not indicated for the prevention of cardiovascular events. Rosuvastatin should be used according to the prescribing information, which contains recommendations for initiating and titrating therapy according to the individual patient profile. In most countries, the usual recommended starting dose of rosuvastatin is 10 mg.

Rosuvastatin 20 mg was well tolerated in nearly 9,000 patients during the course of the study. There was no difference between treatment groups for major adverse events, including cancer or myopathy. There was a small increase in physician reported diabetes consistent with data from other large placebo controlled statin trials.

ABOUT JUPITER:

JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) was a long-term, randomized, double-blind, placebo-controlled, large-scale study of 17,802 patients designed to determine if rosuvastatin 20 mg decreases the risk of heart attack, stroke and other major cardiovascular events in patients with low to normal LDL-C but at increased cardiovascular risk as identified by elevated high-sensitivity C-reactive protein (hsCRP) and age. The majority of patients had at least one other risk factor including hypertension, low HDL-C, family history of premature coronary heart disease (CHD) or smoking. hsCRP is a recognized marker of inflammation which is associated with an increased risk of atherosclerotic cardiovascular events.

JUPITER is a part of AstraZeneca's extensive GALAXY clinical trials
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
6. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
11. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Medina Medical announced today ... member of the Board of Directors on August 18, ... development and commercialization experience, including over a decade of ... served as a Partner of the medical device incubator ... of two Foundry start-ups. Mr. Engelson previously served as ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Peptide Cancer Therapeutics Market & Pipeline Insight 2014" ... methods developed to prevent and eradicate the prevalence of ... methods are confined to low specificity, safety and large ... look for a better solution. It has been discovered ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... incretin mimetic claims continue to move forward in U.S. ... issued by AstraZeneca PLC on July 31, 2014, Byetta ... named in 409 product liability claims that allege the ... documents indicate that many of these claims are pending ...
(Date:8/30/2014)... August 30, 2014 Continuing to meet ... is expanding with the addition of a new doctor ... who has provided leading-edge skin care in Grand Rapids ... , “As a doctor, my passion is making ... partnering with Forefront Dermatology, I’m better able to focus ...
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... result of a car accident," said one of two ... muscle strain in her shoulder and neck area. She ... invented reduced pain and pressure, assisting in comfort and ... the patent-pending PILLOW CRADLE to support the head, neck ...
(Date:8/30/2014)... Market Research Report on Global and ... and in-depth market survey on Global and Chinese ... basic information of Lab Oven including its classification, ... global and China’s top manufacturers of Lab Oven ... market share etc. , The report further analyzes ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... QMed, Inc., (Nasdaq:,QMED) today announced that its subsidiary, QMedCare ... Special Needs Plan in New Jersey. The,Company is working ... and the Centers for Medicare and Medicaid Services (CMS) ... the New Jersey Special Needs,Plan., The Company is ...
... Avalon CEO brings leadership and entrepreneurial expertise to ... ... Dreamerz Foods, Inc., the,creator of Dreamerz, the first ever all-natural sleep ... Products, as the newest member of the San Francisco-based company,s,Board of ...
... Dec. 27 Cogdell Spencer Inc.,(NYSE: CSA ) ... St.,Luke,s Hospital and Health Network of Bethlehem, Pennsylvania to ... 383,000 square,foot project will consist of a cancer center, ... The two medical office buildings are valued between $35 ...
... EL SEGUNDO, Calif., Dec. 27 Computer ... that it has signed an extension to,a ... with Sun Microsystems Inc., Under the ... all,applications development and support services for Sun,s ...
... Sciences (NIEHS), part of the National Institutes of ... for the first year of funding to three ... Through Specialized Clinically-Oriented Ventures in Environmental Research. The ... gap between basic research and clinical treatment of ...
... to Commercial Operations, SEATTLE, Dec. 27 ... that it has completed its,acquisition of Zevalin(R) (ibritumomab ... marketing, sales, and development of the drug,in the ... outside the United,States by Bayer Schering under an ...
Cached Medicine News:Health News:Gilbert Pritchard, Jr. Joins Board of Directors at Dreamerz Foods, Inc. 2Health News:Gilbert Pritchard, Jr. Joins Board of Directors at Dreamerz Foods, Inc. 3Health News:Cogdell Spencer Announces a $100 Million Development at St. Luke's Riverside Outpatient Campus In Bethlehem, Pennsylvania 2Health News:CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems 2Health News:NIEHS awards DISCOVER grants 2Health News:NIEHS awards DISCOVER grants 3Health News:Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States 2Health News:Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States 3Health News:Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States 4Health News:Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States 5
... Richard-Allan Scientific Resolve Immersion Oil ... allows light transmission throughout most of ... in both low and high viscosity, ... a refractive index of 1.5150. Resolve ...
Immersion Oil, 1,250 cs...
... Type DF is the highest resolution ... microscopy and it also exhibits extremely ... FF has virtually zero fluorescence and ... oil of choice when low levels ...
... and monitors the movement of blood products ... Courier provides a complete audit trail of ... BloodTrack Courier electronically records a blood units ... receipt of blood products through to the ...
Medicine Products: